Dr. Siim Pauklin – Targeted Cancer Therapy – Best Researcher Award

 

Dr. Siim Pauklin - Targeted Cancer Therapy - Best Researcher Award

University of Oxford - United Kingdom

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Siim Pauklin embarked on his academic journey with a Bachelor's degree in Molecular and Cell Biology from the University of Tartu in Estonia, earning the distinction of Diploma Cum Laude in 2004. He further pursued his academic interests with a Master's degree in Molecular and Cell Biology at the same institution, completing it with distinction in 2005. His early academic pursuits showcased exceptional dedication and achievement in the field.

PROFESSIONAL ENDEAVORS:

Following his Master's degree, Siim Pauklin expanded his academic horizons with a Ph.D. in Biochemistry and Molecular Biology at University College London / CRUK London Research Institute from September 2005 to October 2009. His Ph.D. research, titled "Regulation of Activation Induced Deaminase (AID)," not only earned him the prestigious Pontecorvo prize for the best thesis in CRUK but also led to groundbreaking discoveries in the regulation of AID expression by hormones and its role in immune responses, autoimmune diseases, and tumorigenesis.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

Siim Pauklin's research has been instrumental in advancing our understanding of stem cell biology and cancer research, particularly in the molecular mechanisms regulating cancer stem cell formation. His work on the TGFß/Activin/Nodal-SMAD2/3 signaling pathway in pancreatic ductal adenocarcinomas and cancer stem cells has paved the way for insights into chemoresistance, metastatic capacity, and the 3D chromatin architecture of pancreatic cancer.

IMPACT AND INFLUENCE:

Siim Pauklin's impact in the field is evident from his career trajectory, securing prestigious fellowships, awards, and recognition for his significant contributions. His leadership as a Principal Investigator and CRUK Career Development Fellow at the University of Oxford underscores his influence in the scientific community.

LEGACY AND FUTURE CONTRIBUTIONS:

Siim Pauklin's research focus on Targeted cancer therapy and pancreatic cancer. As he continues to lead his research group at the University of Oxford, his commitment to uncovering early detection methods and advancing therapeutic strategies for cancer stem cells promises a lasting impact on the field. His future contributions are anticipated to further shape our understanding of cancer biology and contribute to the development of novel cancer therapies.

NOTABLE PUBLICATIONS

BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma. 2023

KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics. 2023

Epigenetic and transcriptional regulations prime cell fate before division during human pluripotent stem cell differentiation.2023

 

 

 

 

Mr.Christopher Olowosoke – Targeted Cancer Therapy – Best Researcher Award

Mr.Christopher Olowosoke - Targeted Cancer Therapy - Best Researcher Award

Federal University of Technology Akure - Nigeria

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS

Christopher Busayo Olowosoke embarked on his academic journey with a focus on biotechnology. His dedication to academic excellence was evident during his West African Senior School Certificate Examination at Isefun Community Senior Secondary School, Lagos State, Nigeria, where he achieved a grade of Distinction in the Science stream. This early success set the stage for his future pursuits in the field of biotechnology and information technology.

PROFESSIONAL ENDEAVORS

With a passion for biotechnology and an interest in the chemistry of natural products and pharmacology, Christopher pursued his first degree at the Federal University of Technology, Akure, Ondo State, Nigeria. Graduating with an outstanding grade of 4.73/5.00 in Biotechnology in 2020, he showcased his commitment to academic excellence. His undergraduate thesis, "Identification of pungency-associated genes in some indigenous Nigerian hot pepper varieties," demonstrated his engagement with cutting-edge research.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

As a Student Research Assistant at the Federal University of Technology, Akure, Christopher actively contributed to research in the Departments of Biochemistry, Biotechnology, and Microbiology from 2017 to 2021. His involvement in in vivo, in vitro, and in silico procedures for diabetes and  targeted cancer therapy underscored his commitment to addressing metabolic and cellular proliferation dysregulation, aligning with Sustainable Development Goal 3 (SDG 3). Additionally, his work on the phyto-treatment of diabetes using Andrographic paniculata showcased his dedication to innovative therapeutic approaches.

IMPACT AND INFLUENCE

Christopher's impact extended beyond the laboratory. As a Laboratory Research Assistant at Chrisland University Biotechnology Department from 2022 to the present, he played a pivotal role in organizing practical sessions and providing training in bioinformatics and molecular biology for undergraduates. His leadership as the Founder of B.Khrease Academic Consult since 2018 highlights his commitment to facilitating student projects, mentorship, and collaboration with academic experts.

ACADEMIC CITES

Christopher's research contributions are recognized through his publications. His paper titled "Multiregulator of EZH2-PPARs Therapeutic Targets" was published in Applied Biochemistry and Biotechnology in 2023. This publication addresses critical aspects of pancreatic insulin production and cancer dysregulation. The link to his full publication list on ResearchGate (https://www.researchgate.net/profile/Christopher-Olowosoke/research) reflects his ongoing scholarly pursuits.

LEGACY AND FUTURE CONTRIBUTIONS

Christopher's legacy includes leadership roles, such as being the Founder of B.Khrease Academic Consult and serving as the Promotional and Development Committee Head at the Institute of Bioinformatics and Molecular Therapeutic (IBMT) since 2021. His active participation in conferences, workshops, and professional webinars, as well as affiliations with prestigious societies, showcases his commitment to staying at the forefront of biotechnological advancements.

AWARDS/GRANT

Christopher's achievements are acknowledged through various awards and grants, including being a beneficiary of the American Society for Nutrition Early Career Professional Mentoring Program in 2023 and securing the second position in the Peeref International Best Poster Presentation in the same year. His involvement in securing the TETFUND Grant Award for the Biotechnology Department in 2022 and the UNESCO-ICB Scholarship in 2020 further demonstrates his capacity to contribute significantly to his field.

NOTABLE PUBLICATION

Multi-regulator of EZH2-PPARs Therapeutic Targets: A Hallmark for Prospective Restoration of Pancreatic Insulin Production and Cancer Dysregulation.